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Anti-Müllerian hormone (AMH) is a very sensitive indicator of the ovarian follicular content. Chemotherapeutic
agents are notoriously ovariotoxic in that they damage follicles. The aim of this systematic review was to investigate
the interest of serum AMH variations in determining the acute and long-term effects of chemotherapy on the
ovarian reserve. According to the PRISMA guidelines, searches were conducted on PubMed for all English language
articles until December 2013. Fifteen articles that focused on dynamic variations of AMH levels before and after
chemotherapy were selected. Cancer patients have significantly lower AMH after chemotherapy than age-matched
controls. Longitudinal studies of AMH variations before, during and after chemotherapy provide information about
the degree of follicle loss for each patient according to different chemotherapy regimens. Different patterns of
AMH levels during the ovarian recovery phase make it possible to discriminate between high and low gonadotoxic
chemotherapy protocols. In addition, pretreatment AMH levels are shown to predict the long-term ovarian function
after the end of treatment. These results may help to better understand the ovarian toxicity mechanisms of
chemotherapy and to predict the degree of the ovarian follicle loss. Therefore, it can be useful for fertility
preservation strategies, fertility counseling and future family planning.
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With the continuous improvement of cure rate over the
last few decades, ovarian function resurgence and repro-
ductive capacity after cancer treatment have become im-
portant quality-of-life issues. Chemotherapy regimens,
particularly those including alkylating agents, are notori-
ously ovariotoxic by damaging all kinds of follicles from
primary to preantral and antral stages [1-4]. The precise
mechanisms of this toxicity are uncertain. Increased
apoptotic processes seem to be the main factor [3,5-9],
although cortical fibrosis and blood vessel injury are also
described [10,11]. It is now well-established that the de-
gree of this ovarian toxicity is highly dependent on age,
treatment and dosage [5,12]. Ovarian damage can be
permanent, particularly in the case of protocols including
alkylating agents, leading to premature ovarian failure* Correspondence: maeliss.peigne@chru-lille.fr
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article, unless otherwise stated.and/or infertility [2,3,13]. In other cases, recovery of ovar-
ian function may occur.Chemotherapy and ovarian follicles
The toxicity of alkylating agents has been well studied. Ex-
perimental studies in rats and rhesus monkeys, treated
with cyclophosphamide, have shown that the depletion of
primordial follicles is rapid and drastic [14-16]. Human
ovarian histology following chemotherapy treatments evi-
denced atrophy, reduced follicle store [5,10,17] and espe-
cially, primordial follicle pool loss [18,19]. Furthermore,
one of these studies reported a deep AMH decrease in
mice treated with cyclophosphamide concomitantly with
the histological follicular depletion [16]. Some authors
suggest that this primordial follicle loss can arise in two
different ways. The first would be a direct eliminatory ef-
fect of chemotherapeutic agents on primordial follicles.
The second would be indirect, through an excessive re-
cruitment of the primordial follicles into the growing pool
due to a decrease in Anti-Müllerian Hormone (AMH)Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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shown that AMH-knockout mice exhibit premature acti-
vation and rapid depletion of ovarian follicle reserve [20].
In addition, a recent study showed that cyclophosphamide
triggers upregulation of the PI3K pathway, initiating a
wave of follicle recruitment and growth, and ultimately,
burnout of the ovarian follicle reserve [21].
Oocyte and somatic cells in the ovary can be potential
targets of chemotherapeutic agents, with differential sen-
sitivity to the various types of drugs. In animal models,
cyclophosphamide is well known to induce apoptosis of
pregranulosa and granulosa cells in all classes of follicles
[22]. Oocytes are damaged only in primordial and small
antral follicles [14,22]. A recent study in mice investi-
gated the effect of doxorubicin on the ovarian follicles
and suggested that damage to the oocytes may be mainly
due to somatic cell failure [23]. Using a human ovarian
xenografting model, Oktem and Oktay [8] showed that
primordial follicle density is rapidly affected by apoptosis
after cyclophosphamide injection (12%, 53% and 93% of
follicle loss at 12, 24 and 48 h after the first injection, re-
spectively). Human oocytes are drastically damaged
(100% at 12 h post injection), followed by granulosa cells
(63% at 12 h). The fact that alkylating agents are not
cell-cycle specific and thus, do not require cell prolifera-
tion for their cytotoxic action can explain why resting
follicles are also damaged. While the follicular toxicity of
alkylating agents such as cyclophosphamide is well
defined [2,3,13], that of multi-agent regimens remains
poorly documented.
In addition to the apoptotic phenomenon of granulosa
cells, ovarian stromal tissue could also be damaged by
chemotherapy due to cortical fibrosis and blood vessel
injury [7,10,11]. These phenomena could participate sec-
ondarily to the follicular alteration through impairment
of follicular vascularization.
Most of the studies that have addressed the question
of reproductive capacity after cancer have focused on
markers such as cycle length, pregnancy occurrence and/
or basal FSH values. Nevertheless, recent studies have
shown that follicular depletion may occur despite recovery
of regular menstrual cycles [24-26]. This suggests that
more accurate indicators are needed in order to properly
inform the women about their fertility after treatment.
Recent studies have suggested that AMH could be a valu-
able indicator of follicular depletion in breast cancer
[27-29] and lymphoma patients [24].
AMH and follicles
AMH is a dimeric glycoprotein and belongs to the TGF
β family which acts on tissue growth and differentiation.
Its name comes from its first known function: the re-
gression of Müllerian ducts during male fetal differenti-
ation. In women, serum AMH appears to be exclusivelyof ovarian origin since AMH is undetectable in serum 3
to 5 days following bilateral ovariectomy [30]. AMH is
produced by granulosa cells of preantral and small antral
follicles and its main physiological role seems to be the
inhibition of the initial follicular recruitment from the
primordial to the antral pool [31]. It has been extensively
studied in Assisted Reproductive Therapy processes. It is
now well established that AMH is the more accurate
marker of the ovarian reserve [32]. In women, serum
AMH levels are almost undetectable at birth and pro-
gressively increase to the adult level. It appears to be
stable up to 25–30 years and then to decrease through-
out the remaining reproductive life until being undetect-
able after spontaneous menopause [30,32-36]. AMH level
on day 3 of the menstrual cycle has been shown to be
strongly correlated with the antral follicle count (AFC)
[33] and with the primordial follicule pool [37-41]. Fur-
thermore, AMH measurement is reproducible and easy to
obtain. Highly sensitive ELISA assays are currently avail-
able to measure AMH levels in women: the Gen II assay
and the Immunotech MIS-AMH assay. Both are produced
by the same company (Beckman Coulter). They use dif-
ferent monoclonal antibodies targeting different regions
of AMH and different calibrators thus explaining that
the two assays generate quite different results and are
not interchangeable. The Diagnostic Systems Laborator-
ies (DSL) assay is not used anymore, but has been used
in several studies cited in this review.
Finally, as AMH concentration does not change sig-
nificantly during the menstrual cycle [30,42,43] and is
weakly influenced by short term (< 6 months) gonado-
tropin suppressing treatments [44,45] unlike other fol-
licular markers such as FSH, estradiol, AFC, Inhibin B
[30,42,43], AMH is thus considered as the more specific
and reproducible marker of the ovarian reserve.
This review aims to highlight whether serum AMH could
be a valuable indicator of the acute and long-term effects of
chemotherapy regimen on the ovarian follicular content
and how it could help in better understanding the chemo-
induced toxicity and in fertility preservation strategies.
Methods
A systematic MEDLINE (PubMed) search was performed re-
garding articles published in English containing key words
“AMH” (Anti-Müllerian hormone), “MIS” (Müllerian
Inhibiting Substance), “chemotherapy”, “follicle”, “ovar-
ian reserve”, “ovarian toxicity” and “alkylating agents”.
All the relevant publications were selected until December
2013. We examined the 36 published studies measuring
AMH levels in women who have undergone chemother-
apy for different types of cancer. As this systematic review
aims to focus on dynamic variations of AMH levels prior
to, during and after chemotherapy, we excluded those that
investigated only the post-treatment AMH levels compared
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consideration for this review. All studies are prospective ob-
servational studies including pre and post-chemotherapy
AMH level measurement analysis.
Results and discussion
AMH pre/post chemotherapy
It has been shown that post-chemotherapy AMH levels
are significantly lower than those of age-matched controls
confirming the idea that AMH is a more accurate, direct
and specific indicator of the follicle loss. Nevertheless,
only the comparison of pre/post-chemotherapy AMH
levels would allow the evaluation of the individual degree
of follicular depletion. Studies which addressed this issue
are summarized in Table 1.
In 22 young, regularly menstruating women with breast
cancer, Lutchman-Singh et al. [46] demonstrated that, for
each woman, the post-chemotherapy serum AMH level
was significantly lower than the pre-treatment level. In
this study, pre-treatment AMH levels were not different
between the patients and the control population. Aslam
et al. [47] in a smaller case–control study had the same re-
sults. In contrast, two other studies [48,49] concluded that
ovarian reserve seemed to be already compromised prior
to chemotherapy for haematological malignancy. Indeed,
in both these studies AMH was significantly lower in the
treated group before chemotherapy compared to controls,
even though the latter group was older. In addition, Law-
renz et al. [48] reported that the number of retrieved oo-
cytes for fertility preservation was significantly lower in
patients with lymphoma compared to those with breast
cancer. They hypothesized that haematological malignan-
cies may affect the ovarian reserve in women before
chemotherapy, as it was already suggested in men [50] for
semen quality, through unknown mechanisms.
AMH prior to, during and after chemotherapy
To date, few studies have been designed to prospectively
evaluate the longitudinal variations of AMH levels inTable 1 Summary of studies with pre/post-treatment AMH meas
Study Cancer Number of patients
Lutchman-Singh, 2007 [46] Breast 22
Lie Fong, 2008 [49] Haematological 25
Aslam, 2011 [47] All types 8
Lawrenz, 2012 [48] Lymphoma 38patients treated by chemotherapy. This approach allows
for studying the timing of follicle loss and of putative re-
covery. Five of these studies have been conducted in
pre-menopausal, breast cancer patients [26-29,51], one
in lymphoma patients [24], two in several types of can-
cer [52,53] and two in childhood cancer [54,55]. These
studies are summarized in Table 2 for adult cancers and
Table 3 for childhood cancers.
A marked and prompt fall in serum AMH levels as early
as the first month of chemotherapy has been described in
four longitudinal studies [24,26,53,54]. Decanter et al. [24]
investigated 30 young lymphoma patients (mean age:
24 years) divided into two groups according to the pres-
ence or not of alkylating agents in their chemotherapy
protocol. AMH levels decreased significantly 15 days after
the start of treatment, even in the non-alkylating group.
Rosendahl et al. [53] found the same results as soon as
week 1 after initiation of chemotherapy in 17 patients
treated for lymphoma, breast cancer or Ewing sarcoma, of
which 13 had an ovary removed for cryopreservation.
Brougham et al. [54] recently described the same drastic
AMH fall in 22 prepubertal and pubertal girls (median
age: 4,4 years) treated by various chemotherapy or radio-
therapy protocols for different types of cancer as did
Anderson in 59 early breast cancer patient (mean age:
42.6) as soon as one cycle of chemotherapy [26]. Mörse
et al. [55] and Dillon et al. [52] described this fall of AMH
but only three months after the first cycle of chemother-
apy in, respectively, 34 young patients (mean age: 9,5 years)
and 46 patients (mean age: 26,1 years) treated for different
kinds of cancer. At the end of chemotherapy, these studies
showed significantly decreased or undetectable AMH
levels, independently of protocols. The study of Dillon
et al. [52] is the only study to prove an association be-
tween alkylating agent exposure and post-therapy impair-
ment of AMH but in a very heterogeneous group.
The same significantly decreased or undetectable AMH
levels at the end of chemotherapy was obtained in studies
conducted in breast cancer patients by Anderson et al.,urements in young women undergoing chemotherapy (CT)
Conclusion
-AMH post-CT < AMH pre-CT
-AMH pre-CT = AMH in age-matched controls
-AMH post-CT < AMH pre-CT
-AMH pre-CT < AMH in older controls
-AMH post-CT < AMH pre-CT
-AMH post-CT < AMH in age-matched controls with the same follow-up
-AMH post-CT < AMH pre-CT
-AMH pre-CT < AMH in age-matched controls
-Number of retrieved oocyte for cryopreservervation in
lymphoma < retrieved oocytes in women with breast cancer
Table 2 Summary of studies with longitudinal follow-up of serum AMH levels in young women undergoing chemotherapy (CT) for adult cancer













41 (28–52) Before CT,
every 3 months during CT
56 -Significant fall of AMH levels 3
months after the start of CT.
-Undetectable values of AMH in
most patients at the end of CT.
-Different degrees of gonadotoxicity
according to protocols.





40 (21–51) Before CT,
3 to 6 weeks post CT,
6 months and year post CT
38 -Undetectable values of AMH in most
patients at the end of CT and one year
post-CT.
-Pre-CT AMH levels lower among women who
became amenorrheic compared to those who
resumed menses.
Decanter, 2010 [24] Lymphoma Alkylating or non
Alkylating regimens
24 (18–32) Before CT,
15 days after first cycle,
15 days before last cycle,
every 3 months after CT until
1 year
30 (17 non alkylating
protocol,
13 alkylating protocol)
No difference between protocols
regarding the depletion phase:
-Acute fall of AMH as soon as 15
days after the start of CT.
-Undetectable values of AMH at the
end of CT in both protocols.
Different recovery phases according to protocol:
-Very low or undetectable AMH levels
in the alkylating group 1 year post-CT.
-Return to pre-treatment values of AMH as
soon as the 6th month of follow-up in the
non-alkylating group.
Rosendahl, 2010 [53] Lymphoma,
Breast cancer,
Ewing sarcoma
7 different protocols 30 (19–35) Before CT, one week after
each CT
or every 2 weeks until
16 weeks of treatment,





-Acute fall of AMH levels as soon as
one week after the first cycle of CT.
-Undetectable values of AMH in most
patients at the end of CT.
-Significantly lower AMH one year after the end of
CT in case of alkytlating protocols than in case of
non alkylating ones.
Yu, 2010 [29] Breast cancer 3 different protocols
all including
alkylating agents
37 (27–40) Before CT, 6, 12, 36
and 52 weeks after first CT
26 -Significant fall of AMH levels 6 weeks after
the start of CT.
-Undetectable values of AMH in most patients
at the end of CT.
-Undetectable AMH levels in all patient
but one 52 weeks after first CT.





41 (28,6-52,7) Before CT, 2,3,4
and 5 years post CT
42 -Lower serum AMH levels, 2–5 years after CT,
than pretreatment ones.
-Undetectable AMH in most women,
2–5 years post-CT.
-Pretreatment AMH level is strongly



















Table 2 Summary of studies with longitudinal follow-up of serum AMH levels in young women undergoing chemotherapy (CT) for adult cancer (Continued)
Dillon, 2013 [52] Different types
of cancer
Different protocols 26,1 (15 – 35,9) Before CT, Every 3 month
during and after treatment
46 (33 alkylating
protocol)
Difference between protocols regarding
the depletion phase:
-Significant fall of AMH levels 3 months after
initiation of CT in alkylating and
non-alkylating groups
-Lower AMH at the end of treatment with alkylating
agents compared with unexposed participants
Different recovery phases according to protocol
and to pretreatment AMH level:
-Rate of recovery of AMH 9 months after
CT higher in non alkylating protocol than in
alkylating protocol
-Rate of recovery of AMH 9 months after CT higher
when pre-treatment AMH was >2 ng/ml than when
it was ≤ 2 ng/m
Anderson, 2013 [26] Early stage
breast cancer
8 protocols, 7 including
alkylating agents
42,6 (23,3–52,5) Before CT, after 1 or 2 cycles
of CT, 1 and 2 years post CT
59 -Significant fall of AMH after 1 cycle of CT.
-Undetectable values of AMH in most patients after
2 or more cycles of CT and at 1 year post CT.
-Pretreatment AMH level is strongly predictive of
post CT ovarian function (menses) at 1 and
2 years post CT.
Henry, 2013 [51] Breast cancer 5 protocols all including
alkylating agents except
for 1 patient
41 (25–50) Before CT,
1 month post CT,
1 year post CT.
27 -Undetectable values of AMH in all
patients 1 month post CT.
-Undetectable AMH levels in most



















Table 3 Summary of studies with longitudinal follow-up of serum AMH levels in young girls undergoing chemotherapy (CT) for childhood cancer













4,4 (0,3-15) Before CT, after each CT course,
between 2 and 12 months post CT,
>12 months post CT
22 (9 high gonadotoxic
protocol, 13 medium or
low gonadotoxic protocol)
No difference between protocols
regarding the depletion phase:
-Significant fall of AMH levels from the
third cycle of CT in all protocols.
-Undetectable values of AMH in most
patients at the end of CT.
Different recovery phases
according to protocol:
-Very low or undetectable AMH
levels in the high gonadotoxic group
more than 12 months post CT.
-Return to pre-treatment AMH values
as soon as the 6th month of follow-up
in the medium/low group risk.
Mörse, 2013 [55] Different type
of cancer
Different protocols 9,5 (4,5-16,5) Before CT, Every 3 month
during and after CT
34 (27 alkylating protocol) No difference between protocols
regarding the depletion phase:
-Significant fall of AMH levels 3
months after initiation of CT.
Different recovery phases
according to protocol:
-Very low or undetectable AMH levels in
the group with irradiation below the
diaphragm and/or stem cell transplantation
18 month post follow-up.
-Return to pre-treatment or higher AMH
values as soon as the 15th month of follow-up
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Anderson et al. in 2006 [28] investigated 50 breast can-
cer patients (mean age: 41 years) who were treated by
different regimens of adjuvant chemotherapy, all including
cyclophosphamide. In most of the patients, AMH levels
remained undetectable after treatment. Anders et al.,
Yu et al. and Henry et al. confirmed these results in 44, 26
and 27 premenopausal breast cancer patients, respectively
[27,29]. The drastic AMH fall just after the beginning of
chemotherapy suggests that most of the growing follicles
are damaged. These results are in keeping with those pre-
viously described in the animal models with alkylating
agents [14-16].
Conversely, the pattern of the ovarian recovery phase
greatly differs depending on the protocols. Decanter et al.
[24] showed different ovarian recovery patterns between
the groups with or without alkylating agents. Patients who
were treated with a non-alkylating regimen recovered
their pre-treatment AMH levels, as early as the 6th month
of follow-up. In contrast, in the alkylating regimen group,
AMH values during all the follow-up remained signifi-
cantly different from the pre-treatment value, with very
low or undetectable levels. Rosendahl et al. [53] also re-
ported significantly higher AMH values in patients who
did not receive alkylating agents. All women treated for
breast cancer received alkylating agents and, in the three
studies, serum AMH levels after chemotherapy remained
very low or undetectable in all of them. Likewise, in a
study by Brougham et al. [54], different recovery phases
were also described between the high gonadotoxic risk
group and the medium/low risk group. These groups were
defined depending on chemotherapy drugs, cumulative
dose and exposure (or not) to radiotherapy involving the
ovaries. Indeed, AMH remained undetectable even 3 years
after the end of chemotherapy in the high risk group. In
contrast, in the low/medium risk group, the recovery oc-
curred as soon as 6 months after treatment. The work of
Mörse et al. [55] confirmed these results with undetect-
able AMH levels 18 months after the beginning of chemo-
therapy in patients who received irradiation below the
diaphragm and/or stem cell transplantation. But after
15 months of follow-up in the 7 patients treated for acute
lymphatic leukaemia (5 with alkylating agents), AMH
levels returned to pre-treatment or higher values. In this
last study, distinction between high and low gonadotoxic
risk was not possible because of the heterogeneity of the
recruitment and the small number of patients in each
group. Finally, a recent work of Dillon et al. [52] con-
cluded that the rate of recovery of AMH after the end of
chemotherapy was impacted by the alkylator use. Almost
all women treated for breast cancer received alkylating
agents and, in the five studies, serum AMH levels
remained very low or undetectable during the entire
follow-up after chemotherapy [26-29,51].Only the dynamics of AMH level during the recovery
phase can discriminate between protocols and suggest
different degrees and/or mechanisms of ovariotoxicity.
Presumably, the primordial follicle pool is less damaged
in the case of non-alkylating protocols, therefore allow-
ing the rapid emergence of newly growing and AMH-
secreting follicles. Intriguingly, AMH levels decreased
drastically just after the beginning of chemotherapy
even in the non-alkylating protocol group. Whether this
fall of AMH could reflect either the follicle depletion or
a functional granulosa cell impairment remains to be
established.
Clinical relevance of AMH follow-up in young women
exposed to chemotherapy
Infertility and early menopause are associated with
chemotherapy even in women who resumed menses
after treatment [56]. The probability of early menopause
and infertility depends on the type of cancer, the treat-
ment, and the age at diagnosis [56]. Relationships be-
tween post-chemotherapy AMH levels and ovarian
function, as indicated by menstrual activity, are difficult
to establish. Indeed, among patients in whom AMH
levels remained undetectable at least one year after the
end of chemotherapy, a significant number had already
recovered spontaneous menses [24,25,27-29,53,57]. Con-
versely, all the patients with persisting amenorrhea at
one year of follow-up had undetectable AMH levels
[24,25,28,57]. It may be that ELISA AMH assays cur-
rently available are not sensitive enough to detect very
low values of AMH in women who recovered menses
despite “undetectable” AMH level in the present dosage.
There are very limited data about AMH and spontaneous
conception. One study, by Hagen et al., showed no re-
duced fecundity in young women with a low AMH level
compared to normal AMH [58] but another study showed
that rather older women did show a relationship between
AMH and spontaneous fertility [59]. In addition, it is now
well established that a low AMH level (<0.7 μg/l) is of
poor prognosis in assisted reproductive therapy [32].
Nevertheless, whether a low post-chemotherapy AMH
level predicts the same low chances of conception remains
to be elucidated.
Anderson et al. recently showed that pre-treatment
AMH level is the strongest predictor (better than age) of
menstrual activity at 1, 2 and 4–5 years of follow-up in
two studies including 59 and 42 breast cancer patients
[26,28]. Similarly, Rosendahl et al. [53] showed that high
pre-treatment AMH levels were predictive of higher
AMH levels during recovery of ovarian function after
chemotherapy, independently of patient’s age, removal
or not of one ovary and type of chemotherapy. In the
same way, Dillon et al. [52], very recently, showed a bet-
ter rate of AMH recovery after the end of chemotherapy
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wise, Anders et al. [27] reported that pre-treatment
AMH concentration was lower in women treated for
breast cancer who were amenorrheic one year after
chemotherapy, although Yu et al. have reported no such
difference [29]. Noteworthy, pre-treatment AMH level
can be lower in haematological malignancies before
chemotherapy [48]. The possible causes of the reduced
AMH level in haematological malignancies prior to
chemotherapy are still unclear. Maybe a functional im-
pairment of granulosa cells by compromised general
health or systemic inflammation can explain or contrib-
ute to the reduced AMH level. Very recently, Dorp et al.
[60] described specifically these reduced AMH levels in
very young girls with newly diagnosed cancer. They hy-
pothesized that a decrease in AMH production, an in-
creased metabolism of AMH or a more rapid decline of
the primordial follicle pool might be involved in this re-
duced AMH level. This must be taken into account for
fertility preservation counselling.
Thus, the pre-treatment AMH level may predict the
long-term ovarian function after chemotherapy but the
prognosis of conception when the AMH level is low
after chemotherapy needs to be ascertained. Indeed,
even in young healthy women, the low concentration of
serum AMH is not predictive of reduced fecundability
[58]. Only a long-term and systematic follow-up of ovar-
ian reserve by AMH and of spontaneous fertility in a
large population will allow these issues to be addressed.
Conclusions
Serum AMH is a very convenient and sensitive indicator
of follicular depletion and recovery in young women
during and after chemotherapy. Furthermore, it allows
for the detection of differences in ovarian toxicity be-
tween chemotherapy regimens. A systematic follow-up
of AMH levels in women undergoing gonadotoxic treat-
ment enables the evaluation of the degree of follicular
depletion and recovery. It may help to better understand
the ovarian toxicity mechanisms of chemotherapy. Fur-
thermore, it could be useful to elaborate fertility preser-
vation strategies, fertility counseling and future family
planning, but we must be careful for now since there is
limited data on the prediction of serum AMH on on-
going pregnancy in cancer survivors.
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